Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
autologous bone marrow-derived mononuclear cells (SCARM Institute)
- Development stage
- Unknown
- Lead developer
- Novo Cellular Medicine Institute
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intracoronary, Intramyocardial
01
Overview
Autologous bone marrow-derived mononuclear cells (BM-MNCs) are a heterogeneous population of cells, including hematopoietic stem cells, mesenchymal stem cells, and endothelial progenitor cells, harvested from a patient's own bone marrow. Developed by the Stem Cell and Regenerative Medicine (SCARM) Institute in Tabriz, Iran, this cell therapy is investigated for the treatment of heart failure with reduced left ventricular ejection fraction (LVEF <=30%). The cells are delivered either via intracoronary infusion or direct intramyocardial injection during coronary artery bypass grafting (CABG). The therapeutic mechanism is primarily attributed to paracrine effects, where the injected cells secrete growth factors and cytokines that promote angiogenesis, reduce apoptosis, and modulate inflammation, thereby potentially improving myocardial function and remodeling.
- Other names
- BM-MNCsautologous bone marrow-derived mononuclear stem cellsautologous bone marrow mononuclear cellsABM-MNCs
Beyond the preview
Go deeper on autologous bone marrow-derived mononuclear cells (SCARM Institute).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on autologous bone marrow-derived mononuclear cells (SCARM Institute).